Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 6/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 6/20 | 0.51 |
| ▸ | GABRP | O00591 | 5/20 | 0.51 |
| ▸ | GABRD | O14764 | 5/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 5/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.51 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.51 |
| ▸ | GABRE | P78334 | 5/20 | 0.51 |
| ▸ | GABRA6 | Q16445 | 5/20 | 0.51 |
| ▸ | GABRG1 | Q8N1C3 | 5/20 | 0.51 |
| ▸ | GABRG3 | Q99928 | 5/20 | 0.51 |
| ▸ | GABRQ | Q9UN88 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6024792 | 0.83 | BMP1 (0.49) | — | |
| SCHEMBL6024293 | 0.79 | BMP1 (0.52) | ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL6024832 | 0.78 | GAA (0.52) | ALDH1A1KDM4EHPGDLMNA | |
| SCHEMBL6024345 | 0.78 | BMP1 (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6024637 | 0.77 | BMP1 (0.48) | ALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6023832 | 0.75 | BMP1 (0.58) | POLB | |
| SCHEMBL6023675 | 0.75 | BMP1 (0.48) | — | |
| SCHEMBL6024751 | 0.75 | BMP1 (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6024599 | 0.75 | BMP1 (0.49) | ALDH1A1MAPT | |
| SCHEMBL6024207 | 0.75 | BMP1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363873-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-04-20 | — | — | EP | claimed |
| US-7019003-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-28 | — | — | US | claimed |
| EP-1363873-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-01-04 | — | — | EP | claimed |
| US-20040087585-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2004-05-06 | — | — | US | claimed |
| EP-1363873-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-11-26 | — | — | EP | claimed |
| WO-2002070541-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2002-09-12 | — | — | WO | claimed |
| EP-1363873-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-7019003-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-28 | — | — | US | disclosed |
| EP-1363873-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20040087585-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2004-05-06 | — | — | US | disclosed |
| EP-1363873-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002070541-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087585-A1 | Peptide deformylase inhibitors | PDF, DPEP1, PEPD | GABRA1 4671/4885GABRG2 4631/4885GABRB3 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.